Excluding potential correlations between genetic and epigenetic alterations affecting cyclin-inhibitors and therapy resistance [8,13,14], subsequently, we detected non-sense mutations in the CHEK2 gene (coding for the Chk2 protein) in three patients with primary breast cancers revealing anthracycline resistance [8,15]. This evidence concerns the gene CHEK2 and breast carcinoma.